Compass Therapeutics awaits FDA input on tovecimig biliary cancer dataAug 6Quarterly updateCompass Therapeutics
Compass Therapeutics registers Phase 2 study of CTX-471 in NCAM-positive neuroendocrine tumorsJul 6Trial updateCompass TherapeuticsCTX-471
Sign inSign in